

[New Drug Approvals](#)

Generic Name (Trade Name—Company)

November 29, 2018

Amifampridine

(Firdapse—Catalyst Pharmaceuticals)

FDA approves first treatment for Lambert-Eaton myasthenic syndrome

Uses/Notes

FDA [approved amifampridine](#) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for LEMS.

Efficacy of amifampridine was studied in two clinical trials that together included 64 adult patients who received amifampridine or placebo. The studies measured the Quantitative Myasthenia Gravis score (a 13-item physician-rated categorical scale assessing muscle weakness) and the Subject Global Impression (a 7-point scale on which patients rated their overall impression of the effects of the study treatment on their physical well-being).

For both measures, the patients receiving amifampridine experienced a greater benefit than those on placebo.

The most common adverse effects in the clinical trials were burning or prickling sensation, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. Seizures have been observed in patients without a history of seizures.

Patients should inform their health care provider immediately if they have signs of hypersensitivity reactions, such as rash, hives, itching, fever, swelling, or trouble breathing.

Source URL:

<http://aphanet.org/new-drug-approvals/fda-approves-first-treatment-lambert-eaton-myasthenic-syndrome>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug

therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.